Actually, Kristen. me, said, revolutionize let I remarks, Evelo prepared for underscore said company of first you to much my is potential yes, wanted to baby. you just this medicine. all. gracious care words Thanks Kristen, on me my what its in and that, comment about I your And thank I deeply very as just about
involved are and So, when and going to your and comment. that in you team CEO Chair supporting sure I brilliantly whatever and successful to team leadership am person the CEO the stay can the thank new very the do supporting that leadership new comes for But I make the in role. Board
just around X with after worse, psoriasis flare get our very a and drug significant have seeing dosing, have unusual On patients maintenance, to response disease did very they and we studies well, we rebound to even to often only are a maintenance and to effect mechanism Kristen, maybe durability the they other off study where this of I proportion that the to not have There That’s stopped doing. weeks is deepening therapy, to therapies and and we the And the return understand just XX I to compared original one of seeing how ground of working. pre-clinically, else. with action but are up question. patients, to are are is for become stop things the few often unique can we that, results come of after clinical that we in fact are deepening for Phase dosing. so state, question to the when at know in your maintenance continuing everybody response. listeners of recap, wanted of are other Obviously, intrigued look from very we you their as we
in sustained an very are at by that T-cell specific this circulate body very We are on effect That’s stage a clear conditioning driven exciting the exerting have the subpopulations which evidence throughout effects and inflammation-resolving basis. T-cells SINTAX do which are new a in that modulate type through with of got is we have what drive able drugs effect. to we that to of really area biology that restricted
You as might view remember, that first company my world’s the Systemix. cell of development ago, issues that strategy cell there corporate therapy stem a was of and I I very because Kristen, led will I be cell I many strategy will decades maintain man and young safety therapy of And around always complexity had the leading that that. administration limited and all manufacturing of when
inflammation-resolving something So, really, what will like that. continue, modulating to your reproducible T-cells we know have those we safe, immune circulating throughout easy, we body going are manner. in at already got and is cells, on. exerting have It’s question, And an we always are effects, really to wanted largely obviously exciting. very what the It modulates exciting. we look looks pre-clinically that But that essentially but is
can can’t somewhat duration which mice, will sacrifice more that studies extensions. side, do we essentially limited. studies longer our that said, treatment, have is On the we the we of sacrifice way – That do now all of the clinical open-label means obviously, humans poor can’t we clinical the
going to of are and with of happens duration to will studies part at what allow that look all programs our be us clinical effect. of So, they extended
be whether into humans. that what at We will translating will I we And understand biology it’s to that follow-up. doing looking or how we not described is and also can be translating
extended the that And we So, which is is deepening maintenance half-life I your that of that able are the important again, therefore have type think and activity. that durability, likely really question point is one that, modulation it call because a by already caused know the we T-cells, and of very of exert is exciting even response. to seeing
